PL2289535T3 - Kompozycje i sposoby wspomagania gojenia ran oraz regeneracji tkanek - Google Patents

Kompozycje i sposoby wspomagania gojenia ran oraz regeneracji tkanek

Info

Publication number
PL2289535T3
PL2289535T3 PL10185372T PL10185372T PL2289535T3 PL 2289535 T3 PL2289535 T3 PL 2289535T3 PL 10185372 T PL10185372 T PL 10185372T PL 10185372 T PL10185372 T PL 10185372T PL 2289535 T3 PL2289535 T3 PL 2289535T3
Authority
PL
Poland
Prior art keywords
compositions
methods
wound healing
tissue regeneration
promoting wound
Prior art date
Application number
PL10185372T
Other languages
English (en)
Inventor
Robert Gourdie
Gautam Ghatnekar
Jane Jourdan
Original Assignee
Musc Foundation For Research Development
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Musc Foundation For Research Development filed Critical Musc Foundation For Research Development
Publication of PL2289535T3 publication Critical patent/PL2289535T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
    • C07K14/43581—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies from Drosophila
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/34—Materials or treatment for tissue regeneration for soft tissue reconstruction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Insects & Arthropods (AREA)
  • Cell Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
PL10185372T 2004-12-21 2005-12-20 Kompozycje i sposoby wspomagania gojenia ran oraz regeneracji tkanek PL2289535T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US63836604P 2004-12-21 2004-12-21
US67179605P 2005-04-15 2005-04-15
EP10185372.9A EP2289535B8 (en) 2004-12-21 2005-12-20 Compositions and methods for promoting wound healing and tissue regeneration
EP05855065.8A EP1827480B1 (en) 2004-12-21 2005-12-20 Compositions and methods for promoting wound healing and tissue regeneration
PCT/US2005/046442 WO2006069181A2 (en) 2004-12-21 2005-12-20 Compositions and methods for promoting wound healing and tissue regeneration

Publications (1)

Publication Number Publication Date
PL2289535T3 true PL2289535T3 (pl) 2018-12-31

Family

ID=36593626

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10185372T PL2289535T3 (pl) 2004-12-21 2005-12-20 Kompozycje i sposoby wspomagania gojenia ran oraz regeneracji tkanek

Country Status (17)

Country Link
US (9) US7786074B2 (pl)
EP (4) EP2374469A3 (pl)
JP (2) JP5243040B2 (pl)
KR (1) KR101236450B1 (pl)
AU (1) AU2005319155B2 (pl)
BR (1) BRPI0519737A2 (pl)
CA (1) CA2593979C (pl)
DK (2) DK2377546T3 (pl)
ES (1) ES2620363T3 (pl)
HU (1) HUE038099T2 (pl)
IL (2) IL184045A (pl)
NO (1) NO342964B1 (pl)
NZ (1) NZ556541A (pl)
PL (1) PL2289535T3 (pl)
RU (2) RU2438696C2 (pl)
SG (1) SG158153A1 (pl)
WO (1) WO2006069181A2 (pl)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
WO2005107712A1 (en) 2004-05-03 2005-11-17 Hermes Biosciences, Inc. Liposomes useful for drug delivery
US9408381B2 (en) 2004-12-21 2016-08-09 Musc Foundation For Research Development Alpha Connexin c-Terminal (ACT) peptides for use in transplant
RU2438696C2 (ru) 2004-12-21 2012-01-10 Маск Фаундейшн Фор Рисерч Дивелопмент Композиции и способы, используемые для ускорения заживления ран и регенерации тканей
KR20080031154A (ko) * 2005-02-03 2008-04-08 코다 테라퓨틱스 (엔지) 리미티드 항-코넥신 화합물 및 그의 용도
AU2016203204A1 (en) * 2005-02-03 2016-06-09 Coda Therapeutics Limited Anti-connexin compounds and uses thereof
CA2669832A1 (en) 2006-11-15 2008-05-22 Coda Therapeutics, Inc. Improved methods and compositions for wound healing
CA2670590C (en) * 2006-12-01 2018-06-12 Wake Forest University Health Sciences Medical devices incorporating collagen inhibitors
EP2101791B1 (en) 2006-12-11 2014-09-10 CoDa Therapeutics, Inc. Anticonnexin polynucleotides as impaired wound healing compositions
JP5552048B2 (ja) * 2007-06-21 2014-07-16 ムスク ファンデーション フォー リサーチ ディベロップメント 加齢性黄斑変性を治療するためのアルファコネキシンｃ末端（ａｃｔ）ペプチド
EP2211873B1 (en) * 2007-10-22 2012-08-08 Amorphical Ltd. Stable amorphous calcium carbonate comprising phosphorylated amino acids
CN101970663A (zh) * 2007-12-11 2011-02-09 科达治疗公司 受损伤口愈合的组合物和治疗
EP2245061A2 (en) 2007-12-11 2010-11-03 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
EP2234656A2 (en) 2007-12-21 2010-10-06 Coda Therapeutics, Inc. Improved medical devices
CA2710223A1 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Treatment of surgical adhesions
AU2008343841A1 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of inhibitors of connexin43 for treatment of fibrotic conditions
GB0803352D0 (en) * 2008-02-22 2008-04-02 Ntnu Technology Transfer As Oligopeptidic compounds and uses thereof
WO2009148552A2 (en) * 2008-06-02 2009-12-10 Kansas State University Research Foundation Methods and compositions for treating disease
US8788211B2 (en) 2008-10-31 2014-07-22 The Invention Science Fund I, Llc Method and system for comparing tissue ablation or abrasion data to data related to administration of a frozen particle composition
US9060934B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US9050317B2 (en) 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8545856B2 (en) 2008-10-31 2013-10-01 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US8762067B2 (en) 2008-10-31 2014-06-24 The Invention Science Fund I, Llc Methods and systems for ablation or abrasion with frozen particles and comparing tissue surface ablation or abrasion data to clinical outcome data
US9072799B2 (en) 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US9040087B2 (en) 2008-10-31 2015-05-26 The Invention Science Fund I, Llc Frozen compositions and methods for piercing a substrate
US8518031B2 (en) 2008-10-31 2013-08-27 The Invention Science Fund I, Llc Systems, devices and methods for making or administering frozen particles
US8793075B2 (en) 2008-10-31 2014-07-29 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8603496B2 (en) * 2008-10-31 2013-12-10 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US9050070B2 (en) 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US9072688B2 (en) 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US9060931B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US9060926B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
KR20110105778A (ko) * 2008-11-20 2011-09-27 라이프셀 코포레이션 장루 주위 탈장을 치료하고 예방하는 방법
US20100286762A1 (en) * 2009-03-18 2010-11-11 Musc Foundation For Research Development Compositions and Methods for Ameliorating Clinical Electrical Disturbances
US8609409B2 (en) 2009-06-04 2013-12-17 Clemson University Methods and compositions for cell culture platform
US8680182B2 (en) 2009-06-04 2014-03-25 Clemson University Research Foundation Methods for promoting the revascularization and reenervation of CNS lesions
US20110038921A1 (en) * 2009-08-13 2011-02-17 Clemson University Research Foundation Methods and compositions for temporal release of agents from a biodegradable scaffold
ES2811027T3 (es) * 2010-02-19 2021-03-10 Lifecell Corp Dispositivos para el tratamiento de la pared abdominal
CA2695337A1 (en) * 2010-03-04 2011-09-04 Ian De Belle Compositions and methods for inhibition of hiv
ES2369101B2 (es) * 2010-05-07 2012-08-02 Universidade De Santiago De Compostela Sistema farmacéutico acuoso para la administración de fármacos en las uñas.
US8691771B2 (en) 2010-05-21 2014-04-08 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins for tissue repair
RU2468795C1 (ru) * 2011-05-10 2012-12-10 Государственное образовательное учреждение высшего профессионального образования "Самарский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации Сорбционное, антимикробное и дезодорирующее лекарственное средство для наружного применения
DK2763665T3 (da) * 2011-10-08 2019-11-18 Next Science IP Holdings Pty Ltd Antimikrobielle sammensætninger og fremgangsmåder til anvendelse deraf
EP2793964B1 (en) 2011-12-20 2019-03-20 LifeCell Corporation Sheet tissue products
ES2726105T3 (es) 2011-12-20 2019-10-01 Lifecell Corp Productos de tejido fluidizable
BR112014018047B1 (pt) 2012-01-24 2019-11-26 Lifecell Corp composição de tratamento de tecido
NZ629769A (en) * 2012-03-01 2016-09-30 Firststring Res Inc Topical gels containing alpha connexin c-terminal (act) peptides
US9745548B2 (en) 2012-03-15 2017-08-29 Flodesign Sonics, Inc. Acoustic perfusion devices
US9752113B2 (en) 2012-03-15 2017-09-05 Flodesign Sonics, Inc. Acoustic perfusion devices
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US10689609B2 (en) 2012-03-15 2020-06-23 Flodesign Sonics, Inc. Acoustic bioreactor processes
US10322949B2 (en) 2012-03-15 2019-06-18 Flodesign Sonics, Inc. Transducer and reflector configurations for an acoustophoretic device
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US10737953B2 (en) 2012-04-20 2020-08-11 Flodesign Sonics, Inc. Acoustophoretic method for use in bioreactors
US9999637B2 (en) 2012-04-24 2018-06-19 Lifecell Corporation Functionalized tissue matrices
US9345744B2 (en) 2012-04-25 2016-05-24 Musc Foundation For Research Development Peptide-based collagen modulators for wound healing and tissue repair
TWI474831B (zh) 2012-09-14 2015-03-01 Univ Taipei Medical 免疫調節蛋白於促進傷口癒合或組織損傷治療的用途
US20140112959A1 (en) 2012-10-18 2014-04-24 MiCal Pharmaceuticals LLC - H Series, a Series of MiCal Pharmaceuticals LLC, a Multi-Division Limite Topical steroid composition and method
US20160166637A1 (en) * 2013-08-02 2016-06-16 Virginia Tech Intellectual Properties, Inc. Methods of treating a cancer through targeted disruption of alpha connexin 43-zonula occludens-1 (zo-1) interaction
US9745569B2 (en) 2013-09-13 2017-08-29 Flodesign Sonics, Inc. System for generating high concentration factors for low cell density suspensions
US9725710B2 (en) 2014-01-08 2017-08-08 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
RU2549987C1 (ru) * 2014-06-17 2015-05-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации Средство для ускорения заживления ран и регенерации тканей
US9744483B2 (en) 2014-07-02 2017-08-29 Flodesign Sonics, Inc. Large scale acoustic separation device
CN107109410B (zh) 2014-08-22 2021-11-02 奥克兰联合服务有限公司 通道调节剂
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11420136B2 (en) 2016-10-19 2022-08-23 Flodesign Sonics, Inc. Affinity cell extraction by acoustics
JP7007716B2 (ja) 2015-06-04 2022-01-25 アモーフィカル リミテッド． ポリリン酸塩又はビスホスホネートで安定化した非晶質炭酸カルシウム
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
MA42991A (fr) 2015-10-16 2018-08-22 Ipsen Biopharm Ltd Stabilisation de compositions pharmaceutiques de camptothécine
WO2017180862A1 (en) * 2016-04-13 2017-10-19 Northeast Ohio Medical University Gpnmb compositions for treatment of skin wounds
WO2017180896A1 (en) * 2016-04-14 2017-10-19 Cedars-Sinai Medical Center Gja1 isoforms protect against metabolic stress
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
WO2018039302A1 (en) * 2016-08-23 2018-03-01 The Cleveland Clinic Foundation Cancer treatment using cx26 blocking peptides
CN110121351A (zh) 2016-10-25 2019-08-13 艾玛菲克有限公司 用于治疗白血病的无定形碳酸钙
RU2646792C1 (ru) * 2016-12-13 2018-03-07 Акаев Ислам Умарович Средство для лошадей, обладающее регенеративной активностью
BR112019017087A2 (pt) * 2017-02-16 2020-04-14 Firststring Res Inc composição e métodos para prevenir a lesão por radiação e promover a regeneração do tecido.
CA3061738A1 (en) 2017-04-28 2018-11-01 Auckland Uniservices Limited Methods of treatment and novel constructs
WO2018209169A1 (en) * 2017-05-12 2018-11-15 Ohio State Innovation Foundation Peptides and methods for treating neurodegenerative disorders
EP3650032A4 (en) * 2017-07-07 2021-04-14 Lipobiolab Corporation COMPOSITION FOR THE RELIEF AND TREATMENT OF BURNS AND WOUNDS
WO2019018691A1 (en) 2017-07-19 2019-01-24 Auckland Uniservices Limited MODULATION OF CYTOKINE
CN107446018B (zh) * 2017-08-07 2020-07-17 温州千瑞生物科技有限公司 促进伤口愈合的肽及其应用
CN114900773A (zh) 2017-12-14 2022-08-12 弗洛设计声能学公司 声泳系统及其操作方法、控制声换能器及声学系统的方法
AU2019337636A1 (en) * 2018-09-12 2021-03-25 Xequel Bio, Inc. Nanoparticle formulations and methods of use for alpha connexin c-terminal peptides
CA3146539A1 (en) * 2019-07-08 2021-01-14 Firststring Research, Inc. Compositions and methods for preserving organ transplants
ES2804039A1 (es) * 2019-07-30 2021-02-02 Fund Profesor Novoa Santos Fragmentos peptidicos de cx43 para su uso como agentes senoliticos
CN110606872B (zh) * 2019-10-12 2022-06-21 珠海市雅莎医疗器械有限公司 一种促皮肤创伤修复的抗氧化多肽oa-gl17及其制备方法与应用
KR102251640B1 (ko) 2019-11-27 2021-05-17 서울대학교산학협력단 지방세포 분화 촉진용 펩타이드 및 이를 포함하는 지방세포 분화 촉진용 조성물
KR20210104319A (ko) 2020-02-17 2021-08-25 노태성 궤양 치료를 위한 조성물
CN115803041A (zh) * 2020-04-07 2023-03-14 福斯特斯特林研究公司 用于治疗病毒感染和其它呼吸道病症的并发症的组合物和方法
WO2021226310A2 (en) 2020-05-06 2021-11-11 Ohio State Innovation Foundation Compositions and methods for treating atrial fibrillation
US20240173561A1 (en) 2021-05-21 2024-05-30 Emblation Limited Microwave treatment of tissue
WO2024085246A1 (ja) * 2022-10-21 2024-04-25 株式会社カネカ 認知症の罹患の有無の判定のためのキット及び方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1601438A (pl) 1968-10-17 1970-08-24
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
DE3681787D1 (de) 1985-07-05 1991-11-07 Whitehead Biomedical Inst Expression von fremdem genetischem material in epithelzellen.
JPS62209523A (ja) 1986-03-11 1987-09-14 Fuji Photo Film Co Ltd 感光材料
JP2917998B2 (ja) 1988-02-05 1999-07-12 ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ 修飾された肝細胞およびその用途
EP0432216A1 (en) 1988-09-01 1991-06-19 Whitehead Institute For Biomedical Research Recombinant retroviruses with amphotropic and ecotropic host ranges
US5234809A (en) 1989-03-23 1993-08-10 Akzo N.V. Process for isolating nucleic acid
US6261834B1 (en) 1991-11-08 2001-07-17 Research Corporation Technologies, Inc. Vector for gene therapy
FR2739621B1 (fr) 1995-10-05 1997-12-05 Centre Nat Rech Scient Peptides utilisables comme vecteurs pour l'adressage intracellulaire de molecules actives
DK2314321T3 (da) 1999-01-27 2014-09-08 Coda Therapeutics Inc Formuleringer, der omfatter antisense-nukleotider til connexiner
EP1178817A2 (en) * 1999-05-14 2002-02-13 Arbor Vita Corporation Molecular interactions in haematopoietic cells
US7250397B2 (en) * 2000-02-23 2007-07-31 Zealand Pharma A/S Antiarrhythmic peptides
EP1387692A4 (en) * 2000-11-11 2004-07-21 Arbor Vita Corp MOLECULAR INTERACTIONS IN HEMATOPOETIC CELLS
WO2002088370A2 (en) * 2001-04-30 2002-11-07 Protiva Biotherapeutics Inc. Autogene nucleic acids encoding a secretable rna polymerase
US6867283B2 (en) * 2001-05-16 2005-03-15 Technion Research & Development Foundation Ltd. Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
US20050053918A1 (en) * 2001-05-16 2005-03-10 Technion Research & Development Foundation Ltd. Method of identifying peptides capable of binding to MHC molecules, peptides identified thereby and their uses
CN1827766B (zh) * 2001-06-28 2010-08-25 徐荣祥 体外细胞的培养方法
US6685971B2 (en) * 2001-06-28 2004-02-03 Rongxiang Xu Method and composition for repairing and promoting regeneration of mucosal tissue in the gastrointestinal tract
AU2002321903A1 (en) * 2001-08-03 2003-02-24 Arbor Vita Corporation Molecular interactions in cells
EP1435925A2 (en) * 2001-10-17 2004-07-14 University of Wales College of Medicine Gap junctions and edhf
JP2003238441A (ja) 2002-02-08 2003-08-27 英行 ▲高▼野 血管新生抑制剤
WO2003096981A2 (en) * 2002-05-15 2003-11-27 Seul, Kyung, Hwan Method of modulating angiogenesis
US7560430B2 (en) 2003-02-14 2009-07-14 Human Matrix Sciences, Llc Elastin digest compositions and methods utilizing same
EP2311949A3 (en) 2003-12-03 2012-11-21 Coda Therapeutics (NZ) Ltd Antisense compounds targeted to connexins and methods of use thereof
US9408381B2 (en) 2004-12-21 2016-08-09 Musc Foundation For Research Development Alpha Connexin c-Terminal (ACT) peptides for use in transplant
RU2438696C2 (ru) 2004-12-21 2012-01-10 Маск Фаундейшн Фор Рисерч Дивелопмент Композиции и способы, используемые для ускорения заживления ран и регенерации тканей
KR20080031154A (ko) 2005-02-03 2008-04-08 코다 테라퓨틱스 (엔지) 리미티드 항-코넥신 화합물 및 그의 용도
JP5552048B2 (ja) 2007-06-21 2014-07-16 ムスク ファンデーション フォー リサーチ ディベロップメント 加齢性黄斑変性を治療するためのアルファコネキシンｃ末端（ａｃｔ）ペプチド
JP5879841B2 (ja) * 2011-09-12 2016-03-08 富士ゼロックス株式会社 画像形成装置
EP2586436A1 (en) * 2011-10-31 2013-05-01 Commissariat à l'Énergie Atomique et aux Énergies Alternatives Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitor

Also Published As

Publication number Publication date
US7786074B2 (en) 2010-08-31
DK2377546T3 (en) 2017-02-13
IL206497A (en) 2015-02-26
NO342964B1 (no) 2018-09-10
BRPI0519737A2 (pt) 2009-01-27
US20180071363A1 (en) 2018-03-15
EP1827480B1 (en) 2016-11-09
NO20073654L (no) 2007-09-19
JP2013136595A (ja) 2013-07-11
US10398757B2 (en) 2019-09-03
US9855313B2 (en) 2018-01-02
EP2377546A2 (en) 2011-10-19
RU2582394C2 (ru) 2016-04-27
US20150140060A1 (en) 2015-05-21
RU2438696C2 (ru) 2012-01-10
US8859733B2 (en) 2014-10-14
RU2011139724A (ru) 2013-04-10
US7888319B2 (en) 2011-02-15
EP2377546B1 (en) 2016-11-02
CA2593979C (en) 2018-09-18
JP2008523843A (ja) 2008-07-10
EP2289535A2 (en) 2011-03-02
US8357668B2 (en) 2013-01-22
US8809257B2 (en) 2014-08-19
RU2007127888A (ru) 2009-01-27
IL184045A (en) 2015-08-31
US20130177628A1 (en) 2013-07-11
US20080095819A1 (en) 2008-04-24
JP5243040B2 (ja) 2013-07-24
US20090215665A1 (en) 2009-08-27
EP2289535B8 (en) 2018-08-08
EP2289535A3 (en) 2011-06-22
US20110059173A1 (en) 2011-03-10
WO2006069181A3 (en) 2007-06-14
EP2374469A2 (en) 2011-10-12
HUE038099T2 (hu) 2018-09-28
DK1827480T3 (en) 2017-01-09
EP2377546A3 (en) 2012-01-25
KR20070102998A (ko) 2007-10-22
EP1827480A2 (en) 2007-09-05
AU2005319155A2 (en) 2006-06-29
IL184045A0 (en) 2008-12-29
EP2289535B1 (en) 2018-03-28
EP2374469A3 (en) 2012-01-25
NZ556541A (en) 2011-01-28
WO2006069181A2 (en) 2006-06-29
US20130274206A1 (en) 2013-10-17
AU2005319155B2 (en) 2013-01-31
US9394351B2 (en) 2016-07-19
CA2593979A1 (en) 2006-06-29
JP5602891B2 (ja) 2014-10-08
AU2005319155A1 (en) 2006-06-29
IL206497A0 (en) 2010-12-30
US20170128523A1 (en) 2017-05-11
KR101236450B1 (ko) 2013-02-25
ES2620363T3 (es) 2017-06-28
US8916515B2 (en) 2014-12-23
SG158153A1 (en) 2010-01-29
US20140038880A1 (en) 2014-02-06

Similar Documents

Publication Publication Date Title
PL2289535T3 (pl) Kompozycje i sposoby wspomagania gojenia ran oraz regeneracji tkanek
GB2434983B (en) Methods and compositions for wound healing
ZA200706016B (en) Compositions and methods for promoting wound healing and tissue regeneration
EP1765426A4 (en) WOUND HEALING POLYMER COMPOSITIONS AND METHOD FOR THEIR USE
EP1919502A4 (en) PROTEIN COMPOSITIONS FOR HEALING OF LESIONS AND SKIN REGENERATION
GB2423928B (en) Methods and compositions for treating pain
HK1207009A1 (en) Absorbable hemostat
ZA200701233B (en) Compositions and methods for dermatological wound healing
EP1799129A4 (en) DEVICES AND METHODS FOR ABLATION OF FABRICS
IL188965A0 (en) Devices and methods for anchoring tissue
EP1740103A4 (en) DEVICES AND METHODS FOR ATTACHING FABRIC TO BONE
EP1737482A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES
IL180844A0 (en) Compositions and methods for treating excessive bleeding
EP1933853A4 (en) TREATMENT OF TISSUE DISTRACTION AND COMPOSITION FOR APPLYING THEREOF
EP1906941A4 (en) METHOD FOR TREATING WOUNDS COMPRISING DELAYED RELEASE COMPOSITIONS
EP1809313A4 (en) PROCESS FOR PROMOTING WOUND HEALING
GB0524514D0 (en) Medical wound healing treatment
AU2003291456A8 (en) Methods for promoting wound healing and uses thereof
HK1165261A1 (en) Use of regenerative cells for promoting wound healing
EP1804817A4 (en) METHODS OF PROMOTING WOUND HEALING
IL177100A0 (en) External preparation for treating painful skin wound
GB0702859D0 (en) Dressing for tissue treatment
EP1812032A4 (en) TISSUE FACTOR COMPOSITION AND METHOD
GB0803201D0 (en) Two-part dressing suitable for use in surgery
IL180319A0 (en) Compositions and methods for dermatological wound healing